Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEBE2
- Development stage
- Preclinical
- Lead developer
- Universitat Autònoma de Barcelona
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
HEBE2 is a novel chimeric fusion protein (chronokine) designed to target multiple pathological pathways in Alzheimer's disease (AD) and other age-related neurodegenerative disorders. It is engineered by merging three soluble proteins: soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2), soluble Klotho (sKlotho or sKL), and TIMP metallopeptidase inhibitor 2 (TIMP2). Developed by researchers at the Autonomous University of Barcelona (UAB) and the Vall d'Hebron Research Institute (VHIR), HEBE2 is designed to overcome the limitations of single-target therapies. In preclinical models, HEBE2 has been shown to modulate microglial activation, enhance the phagocytosis of beta-amyloid monomers by ApoE4/4 microglia, increase the secretion of beneficial cytokines (such as IL-6, IL-12 p70, and IL-1b), extend health span, and partially restore altered molecular brain composition.
- Other names
- TIMP2-sTREM2-sKLTIMP-2-sTREM2-sKLTIMP 2-sTREM2-sKLTIMP2-sTREM2-sKlothoTIMP-2-sTREM2-sKlothoTIMP 2-sTREM2-sKlothoTIMP2-sTREM2-sKlotho fusion proteinTIMP-2-sTREM2-sKlotho fusion proteinTIMP 2-sTREM2-sKlotho fusion protein
02
Targets
Aβ (Amyloid-beta peptides and aggregates)APOE (Apolipoprotein E)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)MMP1 (Matrix metalloproteinase-1)MMP14 (Matrix metalloproteinase 14)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on HEBE2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEBE2.